1
|
Taguchi K, Hashimoto M, Tokuno M, Takeoka S, Maruyama T, Yamasaki K, Otagiri M. Qualitative and quantitative status of cytochrome P450s after the administration of a liposomal platelet substitute in rat liver. Xenobiotica 2024:1-5. [PMID: 39087517 DOI: 10.1080/00498254.2024.2385535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2024] [Revised: 07/23/2024] [Accepted: 07/24/2024] [Indexed: 08/02/2024]
Abstract
In the process of the drug development, studies on the cytochrome P450 (CYP) profiles after its administration provided fundamental information regarding drug interactions with concomitantly administered drugs. Here, we evaluated the influence of the administration of H12-(ADP)-liposomes, a platelet substitute, on the mRNA and protein expression, and metabolic activity of CYPs, with focus on the CYP1A2, CYP2C11 and CYP3A2, in rat liver.At 24 h after administering saline or H12-(ADP)-liposomes (10 mg of lipids/kg), a quantitative RT-PCR and western blot analysis revealed that the mRNA and proteins expression of all of the target hepatic CYP isoforms were not different between the saline and H12-(ADP)-liposome groups. Furthermore, an ex vivo CYP metabolic activity assay showed that hepatic CYP metabolic activities in the H12-(ADP)-liposome group were comparable to the corresponding saline group. On the other hand, the area under the blood concentration-time curve for substitutes for CYP1A2 and CYP2C11 was higher in H12-(ADP)-liposome group than in saline group, but the degree of elevations was negligible levels.At a minimum, based on these results, we conclude that H12-(ADP)-liposomes have no quantitative and qualitative effect on the hepatic CYP isoforms, indicating that the drug interactions of H12-(ADP)-liposomes with CYP-metabolizing drugs would be negligible.
Collapse
Affiliation(s)
| | - Mai Hashimoto
- Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
| | - Masahiro Tokuno
- Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
| | - Shinji Takeoka
- Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
| | - Toru Maruyama
- Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
| | - Keishi Yamasaki
- Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
- DDS Research Institute, Sojo University, Kumamoto, Japan
| | - Masaki Otagiri
- Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
- DDS Research Institute, Sojo University, Kumamoto, Japan
| |
Collapse
|
2
|
Sung AD, Yen RC, Jiao Y, Bernanke A, Lewis DA, Miller SE, Li Z, Ross JR, Artica A, Piryani S, Zhou D, Liu Y, Vo-Dinh T, Hoffman M, Ortel TL, Chao NJ, Chen BJ. Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding. Radiat Res 2020; 194:162-172. [PMID: 32845987 DOI: 10.1667/rade-20-00016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Accepted: 05/07/2020] [Indexed: 11/03/2022]
Abstract
Thrombocytopenia (TCP) may cause severe and life-threatening bleeding. While this may be prevented by platelet transfusions, transfusions are associated with potential complications, do not always work (platelet refractory) and are not always available. There is an urgent need for a synthetic alternative. We evaluated the ability of fibrinogen-coated nanospheres (FCNs) to prevent TCP-related bleeding. FCNs are made of human albumin polymerized into a 100-nm sphere and coated with fibrinogen. We hypothesized that FCNs would bind to platelets through fibrinogen-GPIIb/IIIa interactions, contributing to hemostasis in the setting of TCP. We used two murine models to test these effects: in the first model, BALB/c mice received 7.25 Gy total-body irradiation (TBI); in the second model, lower dose TBI (7.0 Gy) was combined with an anti-platelet antibody (anti-CD41) to induce severe TCP. Deaths in both models were due to gastrointestinal or intracranial bleeding. Addition of antiplatelet antibody to 7.0 Gy TBI significantly worsened TCP and increased mortality compared to 7.0 Gy TBI alone. FCNs significantly improved survival compared to saline control in both models, suggesting it ameliorated TCP-related bleeding. Additionally, in a saphenous vein bleeding model of antibody-induced TCP, FCNs shortened bleeding times. There were no clinical or histological findings of thrombosis or laboratory findings of disseminated intravascular coagulation after FCN treatment. In support of safety, fluorescence microscopy suggests that FCNs bind to platelets only upon platelet activation with collagen, limiting activity to areas of endothelial damage. To our knowledge, this is the first biosynthetic agent to demonstrate a survival advantage in TCP-related bleeding.
Collapse
Affiliation(s)
- Anthony D Sung
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| | | | - Yiqun Jiao
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| | | | | | | | - Zhiguo Li
- Department of Biostatistics & Bioinformatics
| | - Joel R Ross
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| | - Alexandra Artica
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| | - Sadhna Piryani
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| | - Dunhua Zhou
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| | - Yang Liu
- Department of Biomedical Engineering, Pratt School of Engineering
| | - Tuan Vo-Dinh
- Department of Biomedical Engineering, Pratt School of Engineering.,Department of Chemistry, Duke University, Durham, North Carolina
| | | | - Thomas L Ortel
- Division of Hematology, Department of Medicine.,Department of Pathology
| | - Nelson J Chao
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| | - Benny J Chen
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, and Duke Cancer Institute
| |
Collapse
|
3
|
Son K, Ueda M, Taguchi K, Maruyama T, Takeoka S, Ito Y. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes. J Control Release 2020; 322:209-216. [PMID: 32194174 DOI: 10.1016/j.jconrel.2020.03.022] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 01/27/2020] [Accepted: 03/16/2020] [Indexed: 02/06/2023]
Abstract
Using polyethylene glycol (PEG) to functionalize liposomes improves their stealth properties and stability in blood. However, PEG is known to induce the accelerated blood clearance (ABC) phenomenon, which occurs for multiple doses owing to anti-PEG IgM being produced after the initial injection. In this study, as an alternative to PEG, polysarcosine (PSar) was selected owing to its low antigenicity and its highly dense chains with controllable lengths, similar to PEG. Furthermore, we directly evaluate the potential of PSar for avoiding the ABC phenomenon by comparing PSar with PEG on the same liposome platform, which has similar physicochemical properties such as hydrophobic region, membrane fluidity, and size. PEG- and PSar-liposomes were prepared and characterized for comparison. PSar-liposomes showed similar physicochemical properties to PEG-liposomes in terms of size control, zeta potential, membrane polarity, and fluidity; however, ELISA results showed noticeably lower levels and faster production speeds of both IgM and IgG for PSar-liposomes than for PEG-liposomes. In addition, a pharmacokinetics experiment with multiple injections showed that PSar-PE coating of liposomes may help to circumvent the ABC phenomenon.
Collapse
Affiliation(s)
- Kon Son
- RIKEN Cluster for Pioneering Research (CPR), Japan; School of Advanced Science and Engineering, Waseda University, Japan.
| | - Motoki Ueda
- RIKEN Cluster for Pioneering Research (CPR), Japan; RIKEN Center for Emergent Matter Science (CEMS), Japan.
| | - Kazuaki Taguchi
- Faculty of Pharmacy, Keio University, Japan; Faculty of Pharmaceutical Sciences, Sojo University, Japan.
| | - Toru Maruyama
- Graduate School of Pharmaceutical Science, Kumamoto University, Japan.
| | - Shinji Takeoka
- School of Advanced Science and Engineering, Waseda University, Japan.
| | - Yoshihiro Ito
- RIKEN Cluster for Pioneering Research (CPR), Japan; RIKEN Center for Emergent Matter Science (CEMS), Japan.
| |
Collapse
|